Genetic predictors of response to specific drugs in primary myelofibrosis

Blood Cancer J. 2018 Nov 19;8(12):120. doi: 10.1038/s41408-018-0158-4.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers
  • Combined Modality Therapy
  • Female
  • Humans
  • Janus Kinase 2 / genetics
  • Male
  • Middle Aged
  • Mutation
  • Pharmacogenomic Variants*
  • Primary Myelofibrosis / diagnosis*
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / genetics*
  • Prognosis
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Treatment Outcome

Substances

  • Biomarkers
  • Protein Kinase Inhibitors
  • JAK2 protein, human
  • Janus Kinase 2